Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Cardiology
•
Preventive Cardiology
How do you decide between IL-1 inhibitors, azathioprine, and IVIG for steroid-dependent recurrent/incessant pericarditis?
Related Questions
Which classes of medications are reasonable to consider in cases of acute pericarditis in a patient with G6PD deficiency?
How would you approach the risk-benefit ratio of systemic anticoagulation in certain clinical scenarios such as atrial fibrillation or LV thrombus when a patient's history is also notable for type B aortic dissection or other aortic pathology such as aortic ulceration?
How often do you recommend performing an advanced lipid panel for monitoring of lipid lowering therapy?
How soon would you repeat PET/CT in a patient with cardiac sarcoid after starting treatment with infliximab?
How would you further risk stratify patients with systemic vasculitides and chest pain with atypical features?
When would you consider referring a patient with suspected cardiac sarcoidosis based on PET and MRI for endomyocardial biopsy given degree of patchy involvement, as opposed to initiating empiric immunosuppressive therapies?
What are some immunosuppression regimens to consider in a patient with refractory cardiac sarcoidosis?
Would the diagnostic yield for ABIs or peripheral arterial duplex doppler in a patient with metal rods in both legs be similar or acceptable in comparison to those tests in a patient without metal rods?
How do you approach management of recurrent idiopathic pleuropericarditis?
When would you consider using cardiac MRI over nuclear imaging for functional assessment of ischemic heart disease, since it is class IIa indication in the US but otherwise class I in Europe?
